Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by MustardTiger88on Nov 16, 2016 2:15am
273 Views
Post# 25466935

RE:Understanding Canopy's Profit

RE:Understanding Canopy's ProfitThey report in EBITDA, not GAAP, which isn't good.  With this high of a market cap I can't help but think something's gotta give.

ChasingWiLan wrote: I'm trying to compare Mettrum's earnings to Canopy's, and I'm amazed that no one questions Canopy's accounting practice.

Can someone help me understand their numbers:

$8.5 Million Revenue
$2.8 Million Expense for Sales
$4.0 Million Expense for Administration
$0.5 Million Expense for R&D
Plus many other expenses.

Then somehow there is still room for 
$5.7 Million Profit

The "Biological Assets" hasn't been included because that seems like an accounting trick. It appears they book the inventory and "biological assets" at the expected sales price. The result appears to me that they book sales for everything they grow, before they sell it.

Someone please help me understand?

Currentl Mettrum has 60% of the revenue of Canopy and only 20% of the Market Cap. Hoping understanding thebearnings of both better will help me decide how undervalued Mettrum is.

Thanks,

GLTA




Bullboard Posts